OBJECTIVE In China, vinorelbine plus an anthracycline is a common neoadjuvant regimen for locally-advanced breast cancer （LABC）. Pegylated liposomal doxorubicin （PLD） is an alternate anthracycline formulation with...OBJECTIVE In China, vinorelbine plus an anthracycline is a common neoadjuvant regimen for locally-advanced breast cancer （LABC）. Pegylated liposomal doxorubicin （PLD） is an alternate anthracycline formulation with a more favorable safety profile compared with conventional anthracyclines. METHODS In this open-label trial, 61 women with LABC received up to 6 cycles of PLD 30 mg/m2 on Day 1 and vinorelbine 25 mg/m2 on Days 1 and 8 every 21 days. Hormone receptor and/or HER2 status was not routinely available. RESULTS The overall clinical response rate （primary efficacy endpoint） was 80% （95% CI： 68%-89%）. Two patients achieved a pathological complete response （3%）, with 75% having their tumor down-staged, and 89% proceeding to tumor resection. The most frequent nonhematologic adverse events were stomatitis, fever, rash, and palmar-plantar erythrodysesthesia, with none considered serious. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 10% and 2% of patients, respectively. CONCLUSION PLD plus vinorelbine demonstrated comparable efficacy to conventional anthracyclines plus vinorelbine in the neoadjuvant treatment of LABC, but may offer safety advantages.展开更多
The proportion of patients with early-stage breast cancer undergoing mastectomy exceeds 70%in China/11 among which Auchincloss operation is the major surgical technique for patients with axillary lymph node positive b...The proportion of patients with early-stage breast cancer undergoing mastectomy exceeds 70%in China/11 among which Auchincloss operation is the major surgical technique for patients with axillary lymph node positive breast cancer.In order to standardize the clinical application of modified radical mastectomy of breast cancer,Chinese Society of Breast Surgery(CSBrS)organized domestic experts to conduct literature retrieval and expert discussion on the theoretical basis and technical details of modified radical mastectomy for breast cancer.With reference to the grading of recommendations assessment,development,and evaluation system。展开更多
The role of multigene assays in chemotherapy decision-making in patients with early invasive breast cancer has been widely recognized.In 2017,the American Society of Clinical Oncology(ASCO)clinical guidelines for mult...The role of multigene assays in chemotherapy decision-making in patients with early invasive breast cancer has been widely recognized.In 2017,the American Society of Clinical Oncology(ASCO)clinical guidelines for multigene profiling assays focused on increasing the intensity of recommendations for the clinical use of MammaPrint®.[1]The 8th edition of the American Joint Committee on Cancer(AJCC)staging system,officially launched in 2018,established the concept of prognostic staging for the first time,adding the use of non-anatomical information to evaluate the prognosis.Initially,Oncotype Dx®was recommended for suitable patients based on Level I evidence.Subsequently,five testing techniques,Oncotype Dx®,MammaPrint®,EndoPredict®,PAM50®,and BCI,were formally incorporated into the system.[2]To assist breast disease specialists in China in their selection of appropriate multigene profiling assays and detection methods for patients,and also to instill caution on decision-making with reference to multigene assays,the Chinese Society of Breast Surgery(CSBrS)has,through literature investigation and expert discussion,provided information on the key clinical problems and guidelines for the use of multigene assays,evaluating the evidence with reference to the Grades of Recommendations Assessment Development and Evaluation(GRADE)system.Combined with the availability of these assays in China,the clinical practice guidelines for multigene assays were formulated and published.The purpose of this guideline is to provide a reference for clinicians specializing in breast diseases in China.展开更多
文摘OBJECTIVE In China, vinorelbine plus an anthracycline is a common neoadjuvant regimen for locally-advanced breast cancer （LABC）. Pegylated liposomal doxorubicin （PLD） is an alternate anthracycline formulation with a more favorable safety profile compared with conventional anthracyclines. METHODS In this open-label trial, 61 women with LABC received up to 6 cycles of PLD 30 mg/m2 on Day 1 and vinorelbine 25 mg/m2 on Days 1 and 8 every 21 days. Hormone receptor and/or HER2 status was not routinely available. RESULTS The overall clinical response rate （primary efficacy endpoint） was 80% （95% CI： 68%-89%）. Two patients achieved a pathological complete response （3%）, with 75% having their tumor down-staged, and 89% proceeding to tumor resection. The most frequent nonhematologic adverse events were stomatitis, fever, rash, and palmar-plantar erythrodysesthesia, with none considered serious. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 10% and 2% of patients, respectively. CONCLUSION PLD plus vinorelbine demonstrated comparable efficacy to conventional anthracyclines plus vinorelbine in the neoadjuvant treatment of LABC, but may offer safety advantages.
文摘The proportion of patients with early-stage breast cancer undergoing mastectomy exceeds 70%in China/11 among which Auchincloss operation is the major surgical technique for patients with axillary lymph node positive breast cancer.In order to standardize the clinical application of modified radical mastectomy of breast cancer,Chinese Society of Breast Surgery(CSBrS)organized domestic experts to conduct literature retrieval and expert discussion on the theoretical basis and technical details of modified radical mastectomy for breast cancer.With reference to the grading of recommendations assessment,development,and evaluation system。
文摘The role of multigene assays in chemotherapy decision-making in patients with early invasive breast cancer has been widely recognized.In 2017,the American Society of Clinical Oncology(ASCO)clinical guidelines for multigene profiling assays focused on increasing the intensity of recommendations for the clinical use of MammaPrint®.[1]The 8th edition of the American Joint Committee on Cancer(AJCC)staging system,officially launched in 2018,established the concept of prognostic staging for the first time,adding the use of non-anatomical information to evaluate the prognosis.Initially,Oncotype Dx®was recommended for suitable patients based on Level I evidence.Subsequently,five testing techniques,Oncotype Dx®,MammaPrint®,EndoPredict®,PAM50®,and BCI,were formally incorporated into the system.[2]To assist breast disease specialists in China in their selection of appropriate multigene profiling assays and detection methods for patients,and also to instill caution on decision-making with reference to multigene assays,the Chinese Society of Breast Surgery(CSBrS)has,through literature investigation and expert discussion,provided information on the key clinical problems and guidelines for the use of multigene assays,evaluating the evidence with reference to the Grades of Recommendations Assessment Development and Evaluation(GRADE)system.Combined with the availability of these assays in China,the clinical practice guidelines for multigene assays were formulated and published.The purpose of this guideline is to provide a reference for clinicians specializing in breast diseases in China.
